Navigation Links
Treatment target identified for a public health risk parasite
Date:11/26/2013

This news release is available in French.

Montreal, November 26, 2013 In the developing world, Cryptosporidium parvum has long been the scourge of freshwater. A decade ago, it announced its presence in the United States, infecting over 400,000 people the largest waterborne-disease outbreak in the county's history. Its rapid ability to spread, combined with an incredible resilience to water decontamination techniques, such as chlorination, led the National Institutes of Health (NIH) in the United Sates to add C. parvum to its list of public bioterrorism agents. Currently, there are no reliable treatments for cryptosporidiosis, the disease caused by C. parvum, but that may be about to change with the identification of a target molecule by investigators at the Research Institute of the McGill University Health Centre (RI-MUHC). The findings of this study have been recently published in the Antimicrobial Agents and Chemotherapy (AAC) journal.

"In the young, the elderly and immunocompromised people such as people infected with HIV/Aids, C. parvum is a very dangerous pathogen. Cryptosporidiosis is potentially life-threatening and can result in diarrhea, malnutrition, dehydration and weight loss," says first author of the study, Dr. Momar Ndao, Director of the National Reference Centre of Parasitology (NRCP) at the MUHC and an Assistant Professor of the Departments of Medicine, Immunology and Parasitology (Division of Infectious Diseases) at McGill University.

The oocysts of C. parvum, which are shed during the infectious stage, are protected from a thick wall that allows them to survive for long periods outside the body as they spread to a new host. C. parvum is a microscopic parasite that lives in the intestinal tract of humans and many other mammals. It is transmitted through the fecal-oral contact with an infected person or animal, or from the ingestion of contaminated water or food. Since the parasite is resistant to chlorine and difficult to filter, cryptosporidiosis epidemics are hard to prevent.

"Most protozoan (single-celled) parasites like C. parvum use enzymes called proteases to escape the body's immune defenses," explained Dr. Ndao, who is also a researcher in the Infection and Immunity Axis of the RI-MUHC. "In this study, we were able to identify a protease inhibitor that can block the parasite's ability to circumvent the immune system, and hide in intestinal cells called enterocytes, in order to multiply and destroy the intestinal flora."

The discovery, which was made in collaboration with US researchers, is the first time a molecular target has been found for the control of C. parvum. "The next step will be to conduct human clinical trials to develop an effective treatment for this parasite, which affects millions of people around the world," concludes Dr. Ndao.


'/>"/>

Contact: Julie Robert
julie.robert@muhc.mcgill.ca
514-934-1934 x71381
McGill University Health Centre
Source:Eurekalert  

Related biology news :

1. Breakthroughs in Chikungunya research from A*STAR spell new hope for better treatment and protection
2. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
3. Genetic research develops tools for studying diseases, improving regenerative treatment
4. Step forward in research into new treatments for brain edema
5. Marshall University study may lead to new treatments for prostate cancer
6. New discoveries about brain-hand connection sought to improve therapies, treatments, prosthetics
7. Minimally invasive treatment for ruptured aneurysm: Safe, reduces mortality
8. Penn research points to new way of preserving fertility for boys undergoing cancer treatment
9. Researcher who identifed genetic cause and possible treatment for Marfan syndrome honored
10. New discovery may lead to effective prevention and treatment of graft-versus-host dsease
11. Antipsychotic drug may be helpful treatment for anorexia nervosa
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Treatment target identified for a public health risk parasite
(Date:3/17/2016)... 2016 ABI Research, the leader in ... biometrics market will reach more than $30 billion ... 2015. Consumer electronics, particularly smartphones, continue to boost ... to reach two billion shipments by 2021 at ... , Research Analyst at ABI Research. "Surveillance is ...
(Date:3/15/2016)... 15, 2016 Yissum Research Development Company ... company of the Hebrew University, announced today the formation ... technology of various human biological indicators. Neteera Technologies has ... from private investors. ... detection of electromagnetic emissions from sweat ducts, enables reliable ...
(Date:3/14/2016)... , Allemagne, March 14, 2016 ... ) - --> - Renvoi : image ... --> --> ... biométriques, fournit de nouveaux lecteurs d,empreintes digitales pour ... de DERMALOG sera utilisé pour produire des cartes ...
Breaking Biology News(10 mins):
(Date:5/4/2016)... NY (PRWEB) , ... May 04, 2016 , ... ... leveraged recent innovations in biotechnology to help treat hormonal and stress related hair ... Nutrafol® has captured the hearts of key opinion leaders in the medical and ...
(Date:5/3/2016)... ... 2016 , ... Leading CEOs from biotech, pharmaceutical, and healthcare ... 1st at The Four Seasons Hotel Boston. , The Boston CEO Conference is ... access to key decision makers who influence deal making and investment. Attendees gain ...
(Date:5/3/2016)... - And Other Rising Companies ... Those Competitor Biologics  - Biosimilar Drug Producers ... ,  Who are the most important and ... their sales potentials? Discover, in our updated survey, organisations, ... and revenue forecasting. Visiongain,s new ...
(Date:5/2/2016)... 2, 2016 Q BioMed Inc. ... partner Mannin Research Inc. will be attending the Association ... place from May 1-5, 2016 in Seattle ... with its vendors and research partners. The meeting provides ... and other collaborative opportunities for the MAN-01 program for ...
Breaking Biology Technology: